Alcon AG vs F5 Inc — how do they compare? Alcon AG trades at $73.6 (market cap $36.44B), while F5 Inc trades at $418.67 (market cap $23.44B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays a 0.48% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| ALC | FFIV | |
|---|---|---|
Market Cap | $36.44B | $23.44B |
Sector | Health | Technology |
52-Week High | $90.12 | $431.26 |
52-Week Low | $62.02 | $223.99 |
Enterprise Value | $40.28B | $22.08B |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
F5 (FFIV) trades at $414.00, up 0.98% in the last session, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.09 billion in 2025, with a net income margin of 21.95%, while the company raised its annual revenue forecast on robust cybersecurity demand (Reuters, 2026-07-27). The stock is near resistance at $417, with RSI indicating mild overbought conditions.
The outlook remains positive due to consistent earnings outperformance and AI-driven security growth, but risks include high valuation multiples (P/E of 32.98) and competitive pressures. Analysts maintain a moderate buy consensus with a $430.43 price target, suggesting potential upside from current levels.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →